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Background: This study aimed to determine the frequency, nature, and impact of side effects 
associated with the use of brinzolamide-timolol suspension, a topical ocular antihypertensive 
preparation.
Methods: A questionnaire was distributed to 76 consecutive patients attending the Sunderland 
Eye Infirmary Glaucoma Service who were using the brinzolamide-timolol suspension. The 
questions related specifically to effects on daily life, blurring of vision, stinging, irritation, and 
acceptability compared with any drops previously used. Respondents were asked to grade their 
answers to these questions using a numerical scale from 0 to 10.
Results: Seventy-six patients (100%) responded, comprising 58 females and 18 males, aged 
68–95 years, treated for 3–7 months. Quality of life was not significantly affected, with the 
majority of patients recording a response between 0 and 2. Visual blurring was a more prominent 
feature, with the most common scores being 3 and 4. Stinging did not appear to be a prominent 
feature, with 0 as the most common response. Similarly, irritation was not a common finding, 
with most respondents scoring 0 and 1. Finally, the brinzolamide-timolol suspension compared 
favorably with previously used drops, with the vast majority of patients expressing a preference 
for this suspension over other topical medications.
Conclusion: Brinzolamide-timolol suspension appears to be a well tolerated and acceptable 
medication, with minimal effect on patient quality of life.
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Introduction
Glaucoma is a significant cause of visual loss worldwide. Elevated intraocular 
  pressure is the only modifiable therapeutic risk factor for glaucoma-associated 
optic   neuropathy.1 Pharmacologic reduction of elevated intraocular pressure is 
often   associated with a slowing of progressive glaucomatous optic neuropathy and 
  consequent visual loss.2
When first-line medical treatment is deemed to be inadequate, a fixed combination 
of a beta-blocker with either a prostaglandin analog or a carbonic anhydrase inhibitor is 
often used. The advantages of fixed combination products over separate   instillation of 
their constituents are well recognized.1–3 These include avoidance of washout (whereby 
inadequate time is allowed between separate instillations, leading to   suboptimal 
drug absorption), reduced exposure to preservatives, reduced cost, and increased 
  convenience, with subsequent improvement in patient adherence to treatment.
AzargaTM (Alcon Laboratories Inc, Fort Worth, TX) is a fixed combination of 
brinzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker. It is a 
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  suspension with a pH of 7.2 and preserved with   benzalkonium 
chloride 0.10 mg/mL. The concentration of brinzolamide 
is 1% (10 mg/mL) and that of timolol is 0.5% (5 mg/mL).1 
The   combination has been demonstrated to lower intraocular 
  pressure more effectively than either timolol 0.5% or 
  brinzolamide 1% alone dosed twice daily, while providing 
a similar safety profile to that of the individual components.3 
Published data also show that fixed   combinations of 
brinzolamide 1% + timolol 0.5% and dorzolamide 2% + 
timolol 0.5% have similar efficacy for lowering intraocular 
pressure.2,3
Compliance is a key issue in the treatment of glaucoma, 
and a course of therapy that is well tolerated by the patient 
is more likely to be adhered to.4–6 The aim of this study was 
to determine what side effects were experienced by a cohort 
of patients using the brinzolamide-timolol suspension, and 
to investigate their impact, if any.
Methods
The study was conducted at the Glaucoma Unit in the 
  Sunderland Eye Infirmary, Sunderland, UK. A questionnaire 
was prepared, consisting of five questions pertaining to the 
use of brinzolamide-timolol suspension from the patient’s 
perspective (see Figure 1). Each question was assigned 
a numerical scale from 1 to 9, with a verbal option at the 
minimum and maximum of the scale. The questionnaires were 
distributed by one investigator (PSP) to 76 consecutive patients 
using topical brinzolamide-timolol suspension. Each patient 
was handed a questionnaire prior to entering the consulting 
room and given adequate time to complete their responses.
Results
Seventy-six consecutive patients completed the question-
naire, ie, 58 females and 18 males, aged 68–95 years. The 
treatment duration range was 3–7 months. Their responses 
to the questions are shown in Figure 2.
Discussion
The clinical efficacy of brinzolamide-timolol suspension 
was well demonstrated. The fixed combination was found 
to produce statistically significant and more clinically 
relevant reductions in intraocular pressure from baseline than 
brinzolamide 1% or timolol 0.5% over six months of therapy.7 
Michaud and Friren demonstrated that brinzolamide 1% 
twice daily was equivalent to dorzolamide 2% twice daily, 
after treating with timolol 0.5%, in terms of intraocular 
pressure reduction.8 Finally, Manni et al demonstrated that 
the brinzolamide-timolol combination provides a clinically 
relevant intraocular pressure reduction in patients with 
open-angle glaucoma or ocular hypertension that is at least 
as effective as a dorzolamide-timolol combination.2 Given 
that the brinzolamide-timolol combination has a proven 
therapeutic effect, our audit aimed to evaluate its acceptability 
using five different parameters.
1. What effect does your taking Azarga have on your daily life? (minimal answer “no effect”;
maximal answer “completely dominates life”) 
2. To what extent does Azarga cause blurring of your vision? (minimal answer “no effect”;
maximal answer “dreadful”) 
3. How much stinging does Azarga cause? (minimal answer “none”; maximal answer 
“dreadful”) 
4. How much irritation does Azarga cause? (minimal answer “none”; maximal answer “very
severe”) 
5. Compared with previous drops how does Azarga compare? (minimal answer “better”;
maximal answer “worse”) 
Figure 1 Questions in the questionnaire administered to users of brinzolamide-timolol suspension (Azarga™). Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Quality of life
Our survey showed that, in general, our patients’ daily life 
was not greatly affected by use of brinzolamide-timolol 
suspension, with the majority of patients who described any 
effect at all apportioning either 1 or 2 points on the scale.
The relationship between quality of life and use of 
topical glaucoma medication has been studied previously. 
Day et al utilized a patient-reported outcome instrument 
designed to assess patient satisfaction with various attributes 
associated with topical glaucoma medications, including 
side effects, and compliance.9 Patient satisfaction was 
statistically correlated with the perceived effectiveness of 
the medication, ocular irritation, and ease and convenience 
of use. The authors suggested that patient compliance 
might diminish as the satisfaction with their medication 
decreases.
Factors affecting quality of life relating to topical medica-
tions can be categorized according to convenience issues and 
side effects, both ocular and nonocular. The potential benefits 
of the convenience of a fixed-combination medication have 
been described above. Ocular side effects are dealt with 
specifically in the other questions of the survey.
The most common nonocular side effect associated with 
the use of topical carbonic anhydrase inhibitors is dysgeusia, 
ie, distortion of the sense of taste. Brinzolamide has been 
found in a number of studies to cause this side effect. When 
both medications were used in isolation three times daily, 
Silver found brinzolamide to cause more dysgeusia than 
dorzolamide.7 Other studies have found both medications to 
cause this side effect in equal measure, and Manni et al found 
brinzolamide-timolol and dorzolamide-timolol combinations 
to cause dysgeusia to a similar degree.2,8,10
Question 1. What effect does taking Azarga have on your daily life?
Response 
Respondents (n) 
Respondents (n) 
Respondents (n) 
Respondents (n) 
Respondents (n) 
Question 2. To what extent does Azarga cause blurring of your vision? 
Response 
Question 3. How much stinging does Azarga cause? 
Response 
Question 4. How much irritation does Azarga cause? 
Response 
Question 5. Compared with previous drops, how does Azarga compare? 
Response 
“None” 123456789 “Completely
dominates”
“No 
effect”
123456789 “Dreadful”
“None” 123456789 “Dreadful”
“None” 12 34 56789 “Very severe”
“Better” 12 3456789 “Worse”
11 22 20 9422102 3
43 82 52 05 5100 5
32 11 91 07 520000
27 33 12 40 00000 0
31 18 18 00810000
Figure 2 Responses to questionnaire on brinzolamide-timolol suspension (Azarga™) by respondents.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Blurring of vision
Our survey showed that blurring of vision was a significant 
side effect amongst those patients surveyed, with more than 
half of the responders scoring this at either 3 or 4 points on 
the scale. Visual blurring is a known association of brinzo-
lamide use.3 In two independent parallel trials investigating 
ocular comfort, Silver demonstrated a significantly higher 
incidence of transient blurred vision in the brinzolamide 
group compared with the dorzolamide group.4 Stewart et al 
found similar rates of blurring of vision with dorzolamide and 
brinzolamide treatment.10 Studies by Manni et al and Mundorf 
et al report a higher incidence of blurring of vision with the 
brinzolamide-timolol combination than with a dorzolamide-
timolol combination.2,11 Both groups of investigators ascribe 
this finding to the former being a suspension and the latter 
being a solution of lower viscosity.
The subjective impact of blurring appears to be variable. 
In an analysis of eyedrop characteristics, Jampel et al found 
that, of those patients who attributed a symptom to their 
drops, blurred vision was the only symptom they were 
willing to pay more to avoid.12 Conversely, Mundorf et al 
reported that most patients preferred the brinzolamide-
timolol combination, despite the higher rate of blurring of 
vision, suggesting that this effect was less significant than the 
ocular discomfort experienced with the dorzolamide-timolol 
combination.11
Ocular comfort
Some studies have considered the symptoms of “stinging”, 
“pain”, “irritation”, and “burning” together as a group. 
In two independent multicenter trials, Silver demonstrated 
that brinzolamide was significantly more comfortable than 
  dorzolamide.4 Stewart et al confirmed these findings on initial 
instillation and after three days of use.10 Michaud et al found 
that brinzolamide produced significantly less ocular burning 
and stinging than dorzolamide when both were instilled after 
timolol 0.5%.8
Vold et al evaluated the ocular discomfort of brinzolamide-
timolol compared with dorzolamide-timolol.13 Patients 
completed assessments based on burning, stinging, heat or 
warmth, sharp pain, or smarting pain at baseline and after 
one week of treatment. They found significantly less ocular 
discomfort with the former than the latter.
stinging and pain
Our survey differentiated symptoms of stinging and pain 
from those of irritation and burning. The majority of 
respondents in our survey reported none or minimal stinging 
on instillation of the brinzolamide-timolol combination. This 
contrasts with numerous data reporting pain on instilling 
topical dorzolamide.4,7,14 Manni et al reported more pain 
on instillation of dorzolamide-timolol than instillation 
of brinzolamide-timolol.2 Mundorf et al made a similar 
observation, and to a greater degree.11
It is likely that the acceptability of the brinzolamide-
timolol suspension in this regard is due to the relatively 
neutral pH of 7.5 for brinzolamide, as compared with a 
pH of 5.6 for dorzolamide employed to increase aqueous 
solubility.1,4,11,13 The buffering systems used in the 
medications may also affect comfort. Dorzolamide-timolol is 
buffered with sodium citrate, whereas brinzolamide-timolol 
is formulated without any buffering system. It is also possible 
that the comfort differences may be explained by intrinsic 
differences between the two molecules.13
irritation and burning
As with stinging, irritation did not seem to be a significant 
factor amongst our respondents, with 36% of respondents 
reporting no stinging at all, and 95% of respondents scoring 
0, 1, or 2 points for this symptom. Similarly, Manni et al 
found that only 2.7% of patients treated with brinzolamide-
timolol complained of irritation, comparing favorably 
with 10.6% of patients treated with dorzolamide-timolol.2 
Mundorf et al made a similar observation.11 Comparing 
brinzolamide-timolol with brinzolamide alone and with 
timolol alone, Kaback et al specifically elicited symptoms 
of irritation or burning.3 Surprisingly, these authors found 
that the combination and timolol alone caused more irritation 
than brinzolamide when used alone.
Comparison with other drops
In general, the brinzolamide-timolol combination compared 
favorably with other drops previously used by the patients in 
our survey. The most obvious medication to compare with 
brinzolamide-timolol would be dorzolamide-timolol. Three 
studies have compared these fixed combinations directly. 
One study specifically found greater patient preference of 
brinzolamide-timolol over dorzolamide-timolol,11 but all 
studies found the former to be more comfortable than the 
latter.2,11,14
study limitations
This type of study may be subject to bias. The questionnaire 
was administered by the treating clinician in all cases, and 
it is possible that patients may have felt pressured to report 
positive outcomes from the medication in question, in order Clinical Ophthalmology
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to appease the prescribing clinician. Steps were taken to 
minimize this effect:
•	 Questions were designed to be objective and unbiased
•	 Questionnaire was distributed prior to commencement 
of the consultation, and could therefore not have been 
influenced by it
•	 Questionnaire was completed in a private area, separate 
from the consulting physician and consulting room
Finally, a complete list of previous medications used and 
total duration of glaucoma for each patient could have been 
a useful addition to the collected data.
Conclusion
The patients in our study found the brinzolamide-timolol 
  suspension to be comfortable and acceptable, with little 
impact on their daily lives. The comfort advantage offered 
by this suspension has significant implications for improved 
patient compliance, which could result in more effective 
control of elevated intraocular pressure. The brinzolamide-
timolol suspension has an excellent capability to reduce 
intraocular pressure and has high patient acceptance, so is 
becoming an increasingly important therapy for patients with 
primary open-angle glaucoma or ocular hypertension.
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